Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...
Lupin and Merck agreed not to release any financial details of the transaction. The day before, media reports had suggested that the deal might be more than USD 1.5 billion. Citi says business ...
Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...
BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best magic formula stocks for 2025. The Magic Formula, as defined by Joel Greenblatt in his ...
During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BACKGROUND Bacillus Calmette-Guérin (BCG) is one of the most successful vaccines in the world and evidence suggests it can be used as a bacterial vector to deliver heterologous antigens. OBJECTIVES We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback